CKI-7

Research use only, not for human use.

CKI-7 2HCl is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor.

CKI-7 2HCl is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. CKI-7 2HCl also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.

CKI-7 (0.1-10 μM; 5 days; ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner.CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5, indicating that CKI-7 inhibits Wnt signaling. RT-PCR Cell Line:Mouse ES cells Concentration:0.1-10 μMIncubation Time:5 days Result:Significantly increased the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner.Western Blot Analysis Cell Line:Mouse ES cells Concentration:5 μM Incubation Time:5 days Result:Suppressed SFEB-induced β-catenin stabilization on day 5.

In vivo dose-dependent anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilzing a recently isolated Philadelphia chromosome positive acute lymphoblastic leukemia cell line. Standard cell cycle synchronization studies established that exposure to CKI-7 results in cell cycle dependent caspase 3 activation and apoptotic cell death.

CKI-7 2HCl | CKI-7 dihydrochloride | CKI 7 dihydrochloride | CKI7 dihydrochloride | CKI-7 2HCl | CKI 7 2HCl | CKI7 2HCl

Cell Cycle/DNA Damage

ROCK

Cathepsin

——

——

1177141-67-1

358.66

C11H14Cl3N3O2S

>98% (HPLC)

——

Cl.Cl.NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12

——

(-20℃)

With Ice Pack

≥ 2 years